NETT logo

The Boston Neurological Emergencies Treatment Trials (Boston NETT) Group is a team of local hospitals participating in a national, federally-funded research effort to develop new treatments for patients with acute diseases and injuries to the brain, spinal cord, and peripheral nervous system.  Current NETT research studies aim to improve care for patients with stroke and seizures.  Rapid diagnosis and early treatment are critical for improving outcomes in patients with neurologic emergencies, and the NETT will therefore conduct these studies on the front lines of emergency medicine, in cooperation with colleagues in neurology and neurocritical care.

This is an exciting opportunity to improve patient care in the emergency setting.  We appreciate your interest, participation, and feedback.  Welcome to the Boston NETT Group!

Joshua Goldstein, MD, PhD
Principal Investigator
Boston NETT

The Boston NETT Group

Visit the NETT National website

Current NETT studies

These clinical trials are currently enrolling patients at NETT sites nation-wide.

POINT – Platelet Oriented Inhibition in New TIA
Transient ischemic attacks (TIA) are common, with an estimated 250,000-350,000 occurring each year in the US. Patients with TIA often have rapid recovery of blood flow to the brain, which makes TIA different from completed stroke, where recovery is much longer. Many studies have shown that the short-term risk of stroke is high after TIA, particularly in the first few days, even in patients treated with aspirin, which is the current standard of care. Additional effective therapies in those with TIA could significantly reduce the overall burden of stroke if they are started right away. However, no large-scale research study has tested the safety or effectiveness of an acute treatment in patients with TIA. The POINT study aims to determine whether clopidogrel (Plavix) is effective in reducing the 90-day risk of stroke, myocardial infarction (heart attack), and ischemic vascular death when begun within 12 hours of TIA onset in patients taking aspirin.

You can also visit the POINT national study website for more information

SHINE – Stroke Hyperglycemia Insulin Network Effort
SHINE aims to determine the most effective and safest way to control blood sugar levels in patients with an acute stroke and high blood sugar. Patients who enroll in SHINE will receive either insulin intravenous (IV) infusion (in the study treatment group) or saline (salt water) infusion with insulin injections (in the study control group) within 12 hours of the start of their stroke symptoms. Patients who enroll in the study will have their neurological outcomes measured 90 days after their stroke, using an exam called the modified Rankin Scale (mRS) score.  To determine the effectiveness of the treatments, study doctors will compare the 90-day mRS scores of the study treatment and control groups.  To determine the safety of the treatments, the study doctors will look at the rates of low blood sugar and worsening neurological outcomes that occur in both the study treatment and control groups.

You can also visit the SHINE national study website for more information

ESETT - The Established Status Epilepticus Treatment Trial
ESETT is aiming to determine which of 3 FDA approved medications is the best for treating emergency seizures that do not stop, a condition known as status epilepticus. Patients will receive either fos-phenytoin (also known as Cerebyx, or Prodilantin), valproic acid (also known as Depakote), or levetiracetam (also known as Keppra). ESETT will use a special set of rules called Exception From Informed Consent (EFIC) for emergency research. Study-wide ESETT Enrollment for adults aged 18 years and above has been closed, meanwhile the enrollment for children between ages 2 and 18 will be continued until the enrollment target is met.

If you would like to "opt out" or make sure your child is not enrolled in this trial, please click here or contact us at

You can also visit the ESETT national study website for more information.

Contact Us

Center for Neurologic Emergencies
5 Emerson Place, Suite 155
Boston, MA 02114
Phone: 617-726-4597

Joshua N. Goldstein, MD, PhD, FACEP, FAHA
Associate Professor, Harvard Medical School
Director, Center for Neurologic Emergencies
Department of Emergency Medicine
Massachusetts General Hospital
Zero Emerson Place, Suite 3B
Boston, MA 02114
Phone: 617-724-3290

Chun Mei Su
Program Manager, Center for Neurologic Emergencies
Project Manager, Boston NETT/SIREN Group
Department of Emergency Medicine
Massachusetts General Hospital
Five Emerson Place, Suite 119D
Boston, MA 02114
Phone: 617-726-4597

Back to Top